CRDF News and Press, Cardiff Oncology Inc. From 04/20/21

The FDA approval process for vaccines, therapeutics, and other pharmaceuticals was on the nightly news through late 2020. Investors and non-investors alike developed some understanding of that FDA timeline. Medical device clearance is less understood yet critical for investors looking to benef...

Cardiff Oncology Announces Onvansertib Phase 1b/2 Data that Continues to Demonstrate Robust Response to Treatment and Progression-Free Survival in KRAS-Mutated mCRC - 7 of 18 (39%) evaluable patients in the Phase 1b/2 trial have achieved a partial response to-date - Evaluabl...

Cardiff Oncology in Collaboration with MIT Presents Gene Signature Analyses Data Identifying Androgen-Independent Mechanism for Onvansertib-Abiraterone Synergy in mCRPC - Onvansertib and the androgen receptor (AR) signaling inhibitor abiraterone synergize in an AR-independent ma...

Cardiff Oncology Presents Findings from its Expanded Access Program Highlighting the Clinical Benefit of Onvansertib in Heavily Pretreated Patients with Metastatic KRAS-Mutated mCRC - Evaluable participants (n=20) are heavily pretreated (median of 3 prior lines of treatment); an...

Cardiff Oncology to Host Key Opinion Leader Webinar on Onvansertib for the Treatment of KRAS-Mutated Metastatic Colorectal Cancer -- Virtual event will take place on Monday, April 12, 2021 at 11 a.m. ET and will include a Q&A session PR Newswire SAN DIEGO , ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Granted, finding stocks that could double by summer is no easy feat! After all, the markets have been rocky lately. And with interest rates rising, the growth plays have been under lots of pressure and there has been a rota...

The Insurgent AI Innovation Model is a holistic machine learning system that has triggered a strong buy alert for Cardiff Oncology, ranking it in the top 6% of its investment universe. Strong clinical readouts have triggered significant price appreciation that has waned in recent mont...

Cardiff Oncology to Present at the Oppenheimer 31st Annual Healthcare Conference PR Newswire SAN DIEGO , March 11, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing drugs to treat cancers with t...

Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2021 PR Newswire SAN DIEGO , March 10, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing drugs to treat cancers with ...

Cardiff Oncology to Present at H.C. Wainwright Global Life Sciences Conference PR Newswire SAN DIEGO , March 3, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF) , a clinical-stage biotechnology company developing drugs to treat cancers with the...